EOLS Q2 2023 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$49M+32.8% YoY

Gross Profit

$35M70.2% margin

Operating Income

-$15M-30.6% margin

Net Income

-$18M-36.8% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

+18.3%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$169M

Total Liabilities

$176M

Stockholders' Equity

-$7M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$49M	$37M	+32.8%
Gross Profit	$35M	$21M	+62.3%
Operating Income	-$15M	-$21M	+29.2%
Net Income	-$18M	-$23M	+22.7%

Revenue Segments

Product

$49M99%

Service

$666,0001%